Cas:428868-35-3 (7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta[b][1,4]diazepino[6,7,1-hi]indole hydrochloride (1:1) manufacturer & supplier

Chemical Name:(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta[b][1,4]diazepino[6,7,1-hi]indole hydrochloride (1:1)

CAS.NO:428868-35-3

Synonyms:(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta[b][1,4]diazepino[6,7,1-hi]indole hydrochloride (1:1);8H-Cyclopenta[b][1,4]diazepino[6,7,1-hi]indole, 1,2,3,4,7b,9,10,10a-octahydro-, (7bR,10aR)-, hydrochloride (1:1);ps-j-141

Molecular Formula:C₁₄H₁₉ClN₂

Molecular Weight:250.767

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:15.27000

Exact Mass:250.123672

LogP:3.44170

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta[b][1,4]diazepino[6,7,1-hi]indole hydrochloride (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ps-j-141 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta[b][1,4]diazepino[6,7,1-hi]indole hydrochloride (1:1) Use and application,8H-Cyclopenta[b][1,4]diazepino[6,7,1-hi]indole, 1,2,3,4,7b,9,10,10a-octahydro-, (7bR,10aR)-, hydrochloride (1:1) technical grade,usp/ep/jp grade.

Related News: ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. 4-[(E)-4-pyridin-3-ylbut-2-enyl]morpholine manufacturers For these reasons, many pharmaceutical companies are choosing to evaluate biocatalytic processes during early-stage drug development to avoid missing opportunities for capitalizing on these gains. [η(2)-P,P-[2,2-bis(diphenylphosphanylmethyl)-N-methylpropanamine]]tetracarbonylmolybdenum(0) suppliers The FDA in announcing its approval noted that four, 12-week placebo-controlled clinical studies that included a total of 1,143 participants showed Nourianz offered a statistically significant decrease from baseline in daily “off” time compared to those on placebo. [diphenyl(prop-2-ynylsulfanyl)methyl]benzene vendor & factory.